Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Mapping the Site of Action of Human P2X7 Receptor Antagonists AZ11645373, Brilliant Blue G, KN-62, Calmidazolium, and ZINC58368839 to the Intersubunit Allosteric Pocket
Anfal F. Bin Dayel, Richard J. Evans, Ralf Schmid
Molecular Pharmacology (2019) Vol. 96, Iss. 3, pp. 355-363
Open Access | Times Cited: 34

Showing 1-25 of 34 citing articles:

P2X7 in Cancer: From Molecular Mechanisms to Therapeutics
Romain Lara, Elena Adinolfi, Catherine Α. Harwood, et al.
Frontiers in Pharmacology (2020) Vol. 11
Open Access | Times Cited: 136
The purinergic P2X7 receptor as a potential drug target to combat neuroinflammation in neurodegenerative diseases
Francesco Calzaferri, Cristina Ruiz‐Ruiz, Antonio M. G. de Diego, et al.
Medicinal Research Reviews (2020) Vol. 40, Iss. 6, pp. 2427-2465
Open Access | Times Cited: 57
Structural basis for the functional properties of the P2X7 receptor for extracellular ATP
Lin‐Hua Jiang, Emily A. Caseley, Steve P. Muench, et al.
Purinergic Signalling (2021) Vol. 17, Iss. 3, pp. 331-344
Open Access | Times Cited: 45
A current review on P2X7 receptor antagonist patents in the treatment of neuroinflammatory disorders: a patent review on antagonists
Simran Soni, Mihir S. Lukhey, Baban S. Thawkar, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2024) Vol. 397, Iss. 7, pp. 4643-4656
Closed Access | Times Cited: 7
Antagonism of the ATP-gated P2X7 receptor: a potential therapeutic strategy for cancer
Matthew Drill, Nigel C. Jones, Martin Hunn, et al.
Purinergic Signalling (2021) Vol. 17, Iss. 2, pp. 215-227
Open Access | Times Cited: 37
P2X7 Receptors in Neurodegeneration: Potential Therapeutic Applications From Basic to Clinical Approaches
Paul R. Territo, Hamideh Zarrinmayeh
Frontiers in Cellular Neuroscience (2021) Vol. 15
Open Access | Times Cited: 37
Unlocking the therapeutic potential of P2X7 receptor: a comprehensive review of its role in neurodegenerative disorders
Xiaoming Liu, Yiwen Li, Liting Huang, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 5
Characterization of the Active Enantiomer and Mapping of the Stereospecific Intermolecular Pattern of a Reference P2X7 Allosteric Antagonist
Andrew McGown, Nicolas Renault, Amélie Barczyk, et al.
ACS Pharmacology & Translational Science (2025) Vol. 8, Iss. 2, pp. 446-459
Closed Access
UB-MBX-46 is a potent and selective antagonist of the human P2X7 receptor developed by structure-based drug design
Adam Oken, Andreea L. Turcu, Eva Tzortzini, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
The P2X7 receptor antagonist JNJ-47965567 administered thrice weekly from disease onset does not alter progression of amyotrophic lateral sclerosis in SOD1G93A mice
Diane Ly, Anjila Dongol, Peter Cuthbertson, et al.
Purinergic Signalling (2020) Vol. 16, Iss. 1, pp. 109-122
Open Access | Times Cited: 28
Synthesis and Pharmacological Evaluation of Novel Non-nucleotide Purine Derivatives as P2X7 Antagonists for the Treatment of Neuroinflammation
Francesco Calzaferri, Paloma Narros‐Fernández, Ricardo de Pascual, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 4, pp. 2272-2290
Open Access | Times Cited: 24
Alternatively Spliced Isoforms of the P2X7 Receptor: Structure, Function and Disease Associations
Sophie K. F. De Salis, Lanxin Li, Zheng Chen, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 15, pp. 8174-8174
Open Access | Times Cited: 16
Techniques for evaluating the ATP-gated ion channel P2X7 receptor function in macrophages and microglial cells
Raíssa Leite-Aguiar, Victória Gabriela Bello-Santos, Newton G. Castro, et al.
Journal of Immunological Methods (2024) Vol. 532, pp. 113727-113727
Closed Access | Times Cited: 3
P2X 7 receptors exhibit at least three modes of allosteric antagonism
Adam Oken, Ismayn A. Ditter, Nicolas E. Lisi, et al.
Science Advances (2024) Vol. 10, Iss. 40
Open Access | Times Cited: 3
Development and clinical translation of P2X7 receptor antagonists: A potential therapeutic target in coronary artery disease?
Elijah Genetzakis, Jayson Gilchrist, Michael Kassiou, et al.
Pharmacology & Therapeutics (2022) Vol. 237, pp. 108228-108228
Closed Access | Times Cited: 14
Structure-Activity Relationships and Therapeutic Potential of Purinergic P2X7 Receptor Antagonists
Imane Ghafir El Idrissi, Sabina Podlewska, Carmen Abate, et al.
Current Medicinal Chemistry (2023) Vol. 31, Iss. 11, pp. 1361-1403
Closed Access | Times Cited: 8
Role of the P2X7 receptor in breast cancer progression
Yanan Du, Yahui Cao, Wei Song, et al.
Purinergic Signalling (2024)
Closed Access | Times Cited: 2
Involvement of P2 receptors in hematopoiesis and hematopoietic disorders, and as pharmacological targets
Kelly Juliana Filippin, Kamylla Fernanda Souza de Souza, Roberto Theodoro de Araujo Júnior, et al.
Purinergic Signalling (2019) Vol. 16, Iss. 1, pp. 1-15
Open Access | Times Cited: 20
P2X7 receptor: the regulator of glioma tumor development and survival
Damian Matyśniak, Vira Chumak, Natalia Nowak, et al.
Purinergic Signalling (2021) Vol. 18, Iss. 1, pp. 135-154
Open Access | Times Cited: 17
Structural Basis of the Negative Allosteric Modulation of 5-BDBD at Human P2X4 Receptors
Stefan Bidula, Izzuddin Bin Nadzirin, Marco M. D. Cominetti, et al.
Molecular Pharmacology (2021) Vol. 101, Iss. 1, pp. 33-44
Open Access | Times Cited: 16
Design and synthesis of adamantane-1-carbonyl thiourea derivatives as potent and selective inhibitors of h-P2X4 and h-P2X7 receptors: An Emerging therapeutic tool for treatment of inflammation and neurological disorders
Abid Mahmood, Syed Jawad Ali Shah, Jamshed Iqbal
European Journal of Medicinal Chemistry (2022) Vol. 231, pp. 114162-114162
Closed Access | Times Cited: 11
Agonists, Antagonists, and Modulators of P2X7 Receptors
Christa E. Müller, Vigneshwaran Namasivayam
Methods in molecular biology (2022), pp. 31-52
Closed Access | Times Cited: 10
Synthesis of Sulfonamide Tethered (Hetero)aryl ethylidenes as Potential Inhibitors of P2X Receptors: A Promising Way for the Treatment of Pain and Inflammation
Abid Mahmood, Rubina Munir, Muhammad Zia‐ur‐Rehman, et al.
ACS Omega (2021) Vol. 6, Iss. 38, pp. 25062-25075
Open Access | Times Cited: 14
Therapeutic potentials and structure-activity relationship of 1,3-benzodioxole N-carbamothioyl carboxamide derivatives as selective and potent antagonists of P2X4 and P2X7 receptors
Abid Mahmood, Alexander Villinger, Jamshed Iqbal
European Journal of Medicinal Chemistry (2022) Vol. 238, pp. 114491-114491
Closed Access | Times Cited: 9
Identification of a novel P2X7 antagonist using structure-based virtual screening
Gaia Pasqualetto, Marika Zuanon, Andrea Brancale, et al.
Frontiers in Pharmacology (2023) Vol. 13
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top